251 related articles for article (PubMed ID: 20723631)
1. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan.
Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K
Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of pneumococcal polysaccharide vaccine in older adults.
Jackson LA; Neuzil KM; Yu O; Benson P; Barlow WE; Adams AL; Hanson CA; Mahoney LD; Shay DK; Thompson WW;
N Engl J Med; 2003 May; 348(18):1747-55. PubMed ID: 12724480
[TBL] [Abstract][Full Text] [Related]
3. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
[TBL] [Abstract][Full Text] [Related]
4. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia.
Johnstone J; Eurich DT; Minhas JK; Marrie TJ; Majumdar SR
Clin Infect Dis; 2010 Jul; 51(1):15-22. PubMed ID: 20504233
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
[TBL] [Abstract][Full Text] [Related]
6. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated.
Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
Vaccine; 2007 Jun; 25(23):4631-40. PubMed ID: 17478015
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness.
Fedson DS
Semin Respir Infect; 1993 Dec; 8(4):285-93. PubMed ID: 7938925
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population.
Castañeda-Orjuela C; Alvis-Guzmán N; Paternina AJ; De la Hoz-Restrepo F
Vaccine; 2011 Oct; 29(44):7644-50. PubMed ID: 21854825
[TBL] [Abstract][Full Text] [Related]
9. Pneumococcal vaccine in the prevention of community-acquired pneumonia: a skeptical view of cost-effectiveness.
Simberkoff MS
Semin Respir Infect; 1993 Dec; 8(4):294-9. PubMed ID: 7938926
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
Mangtani P; Roberts JA; Hall AJ; Cutts FT
Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
[TBL] [Abstract][Full Text] [Related]
11. Pneumococcal vaccination.
Williams RM
Lippincotts Prim Care Pract; 1998; 2(6):625-33. PubMed ID: 9883157
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal polysaccharide vaccine may not prevent hospitalization for pneumonia in elderly individuals.
Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
Clin Infect Dis; 2007 Feb; 44(4):617; author reply 617-8. PubMed ID: 17260423
[No Abstract] [Full Text] [Related]
13. The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old--Taiwan's PPV vaccination program.
Tsai YH; Hsieh MJ; Chang CJ; Wen YW; Hu HC; Chao YN; Huang YC; Yang CT; Huang CC
Vaccine; 2015 Jun; 33(25):2897-902. PubMed ID: 25936662
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
15. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay.
Pírez MC; Algorta G; Cedrés A; Sobrero H; Varela A; Giachetto G; Montano A
Pediatr Infect Dis J; 2011 Aug; 30(8):669-74. PubMed ID: 21407145
[TBL] [Abstract][Full Text] [Related]
16. Effect of pneumococcal vaccination in hospitalized adults with community-acquired pneumonia.
Johnstone J; Marrie TJ; Eurich DT; Majumdar SR
Arch Intern Med; 2007 Oct; 167(18):1938-43. PubMed ID: 17923592
[TBL] [Abstract][Full Text] [Related]
17. Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.
Rozenbaum MH; Hak E; van der Werf TS; Postma MJ
Clin Ther; 2010 Aug; 32(8):1517-32. PubMed ID: 20728764
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan.
Cai L; Uchiyama H; Yanagisawa S; Kamae I
Kobe J Med Sci; 2006; 52(3-4):97-109. PubMed ID: 16855372
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.
Ochoa-Gondar O; Vila-Corcoles A; Rodriguez-Blanco T; Gomez-Bertomeu F; Figuerola-Massana E; Raga-Luria X; Hospital-Guardiola I
Clin Infect Dis; 2014 Apr; 58(7):909-17. PubMed ID: 24532544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
